Panmure Gordon & Co, a leading independent institutional stockbroker and investment bank, is pleased to advise that it has acted as Nominated Adviser and sole broker on the IPO of Midatech Pharma PLC (MTPH.L) raising £32m. Midatech Pharma PLC, ("Midatech", the "Company" or the "Group"), the nanomedicine company developing and commercialising multiple therapeutic products to enhance the delivery of medicines in major diseases with high unmet medical needs successfully floated on the London Stock Exchange's AIM market following a successful placing by Panmure Gordon (UK) Limited, raising GBP32 million from institutional investors including Woodford Fund Management Limited (19.99% holding after Admission), Arrowgrass Capital Partners LLP (5.3%), Legal & General Investment Management Limited (4.0%) and Octopus Investments Limited (3.6%). Upon Admission, Midatech has completed its acquisition of Q Chip Limited and its subsidiaries ("Q Chip"), a sustained release specialist company based in Wales. Jim Phillips, CEO of Midatech Pharma plc, said: "The proceeds from the IPO will enable Midatech to rapidly move ahead, executing on the strategic plan to become a profitable, fast growth company by moving our own products forward, whilst continuing to partner our core technologies for revenue.”